These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4934606)

  • 21. Studies on the thrombin clotting time. II. The influence of fibrin degradation products.
    Arnesen H
    Scand J Haematol; 1973; 10(4):291-7. PubMed ID: 4764611
    [No Abstract]   [Full Text] [Related]  

  • 22. Major operations, hemostatic parameters and venous thrombosis.
    Korvald E; Abildgaard U; Fagerhol MK
    Thromb Res; 1974 Jan; 4(1):147-54. PubMed ID: 4829665
    [No Abstract]   [Full Text] [Related]  

  • 23. Properties of thrombin and fibrinolysin lysed fibrin.
    Triantaphyllopoulos DC; Muirhead CR; Triantaphyllopoulos E
    Thromb Diath Haemorrh Suppl; 1969; 36():269-76. PubMed ID: 5375545
    [No Abstract]   [Full Text] [Related]  

  • 24. Fibrinogen turnover and drugs acting on fibrinolysis.
    De Nicola P
    Acta Univ Carol Med Monogr; 1972; 52():25-31. PubMed ID: 4544612
    [No Abstract]   [Full Text] [Related]  

  • 25. [Fibrinolytic activity of a protease isolated from Aspergillus ochraceus].
    Klöcking HP; Markwardt F
    Acta Biol Med Ger; 1971; 26(1):35-44. PubMed ID: 5103710
    [No Abstract]   [Full Text] [Related]  

  • 26. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Low-molecular heparin complex formation with the blood coagulation proteins--thrombin and fibrinogen].
    Kudriashov BA; Liapina LA; Pastorova VE; Kondashevskaia MV
    Izv Akad Nauk SSSR Biol; 1992; (5):802-6. PubMed ID: 1332992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental models of defibrination states.
    Lipiński B
    Pol Med J; 1971; 10(3):619-26. PubMed ID: 4256509
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative effects of fibrinogen degradation fragments D and E on coagulation.
    Larrieu MJ; Rigollot C; Marder VJ
    Br J Haematol; 1972 Jun; 22(6):719-33. PubMed ID: 5037875
    [No Abstract]   [Full Text] [Related]  

  • 30. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.
    Kurosawa Y; Nirengi S; Homma T; Esaki K; Ohta M; Clark JF; Hamaoka T
    Sci Rep; 2015 Jun; 5():11601. PubMed ID: 26109079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Organ distribution of fibrin in disseminated intravascular coagulation.
    Regoeczi E; Brain MC
    Br J Haematol; 1969 Jul; 17(1):73-81. PubMed ID: 5807789
    [No Abstract]   [Full Text] [Related]  

  • 32. Oestrogenic treatment of prostatic cancer lowers the fibrinolytic activity in vein walls.
    Carlsson S; Astedt B
    Scand J Urol Nephrol; 1974; 8(3):169-72. PubMed ID: 4139751
    [No Abstract]   [Full Text] [Related]  

  • 33. Sulfatide prolongs blood-coagulation time and bleeding time by forming a complex with fibrinogen.
    Hara A; Uemura K; Taketomi T
    Glycoconj J; 1996 Apr; 13(2):187-94. PubMed ID: 8737243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinogen and its derivatives, hereditary and acquired abnormalities.
    Marder VJ; Buszynski AZ
    Schweiz Med Wochenschr; 1974 Sep; 104(39):1338-42. PubMed ID: 4421373
    [No Abstract]   [Full Text] [Related]  

  • 35. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of defibrinating agents ancrod and reptilase in the treatment of thromboembolism.
    Kwaan HC
    Thromb Diath Haemorrh Suppl; 1973; 56():239-51. PubMed ID: 4617331
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of three cobra venoms on blood coagulation, platelet aggregation, and fibrinolysis.
    MacKay N; Ferguson JC; McNicol GP
    J Clin Pathol; 1969 May; 22(3):304-11. PubMed ID: 5814735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biological half-life of 131 I-labeled fibrinogen from normal and cobalt-treated rabbits].
    Krantz S; Lober M; Oppermann P
    Acta Biol Med Ger; 1972; 29(6):805-10. PubMed ID: 4659761
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of DDAVP on endotoxin-induced intravascular coagulation in rabbits.
    Paloma MJ; Páramo JA; Rocha E
    Thromb Haemost; 1992 Sep; 68(3):306-9. PubMed ID: 1440497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble fibrin complex production and proteolysis during ancrod therapy.
    McKillop C; Edgar W; Prentice CR; Forbes CD
    Scott Med J; 1975 May; 20(3):139-40. PubMed ID: 127379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.